ArticleGene therapy2001
Evidence for nonspecific adsorption of targeted retrovirus vector particles to cells.
Article in Gene therapy, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 58 citations in OpenAlex.
- Paclitaxel-loaded phosphonated calixarene nanovesicles as a modular drug delivery platform.Scientific reports · 2016Article
- Shedding of clinical-grade lentiviral vectors is not detected in a gene therapy setting.Gene therapy · 2015Article
- Article
- A mutant retroviral receptor restricts virus superinfection interference and productive infection.Retrovirology · 2012Article
- Antitumor efficacy of oncolytic herpes simplex virus adsorbed onto antigen-specific lymphocytes.Cancer gene therapy · 2012Article
- Retargeting of viruses to generate oncolytic agents.Advances in virology · 2012Article
- The receptors for gibbon ape leukemia virus and amphotropic murine leukemia virus are not downregulated in productively infected cells.Retrovirology · 2011Article
- Cell entry of enveloped viruses.Advances in genetics · 2011Review
- Entry kinetics and cell-cell transmission of surface-bound retroviral vector particles.The journal of gene medicine · 2010Article
- Directional spread of surface-associated retroviruses regulated by differential virus-cell interactions.Journal of virology · 2010Article
- Cell carriers for oncolytic viruses: Fed Ex for cancer therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2009Review
- Doxorubicin-loaded polymeric micelle overcomes multidrug resistance of cancer by double-targeting folate receptor and early endosomal pH.Small (Weinheim an der Bergstrasse, Germany) · 2008Article
- Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors.Gene therapy · 2008Article
- Identification of host proteins associated with retroviral vector particles by proteomic analysis of highly purified vector preparations.Journal of virology · 2008Article
- Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus.Clinical cancer research : an official journal of the American Association for Cancer Research · 2008Article
- Prolonged adherence of human immunodeficiency virus-derived vector particles to hematopoietic target cells leads to secondary transduction in vitro and in vivo.Journal of virology · 2007Article
- Primary attachment of murine leukaemia virus vector mediated by particle-associated heparan sulfate proteoglycan.The Biochemical journal · 2006Article
- The perforin-dependent immunological synapse allows T-cell activation-dependent tumor targeting by MLV vector particles.Gene therapy · 2006Article
- Porcine endogenous retroviruses infect cells lacking cognate receptors by an alternative pathway: implications for retrovirus evolution and xenotransplantation.Journal of virology · 2004Article
- The Trojan exosome hypothesis.Proceedings of the National Academy of Sciences of the United States of America · 2003Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ability to specifically target a cell-type is important for the development of vectors for in vivo gene therapy. In order to produce retrovirus vectors targeting ovarian cancer cells, which specifically overexpress alpha folate receptor (alphaFR), a single chain antibody was fused as an N-terminal extension of the ecotropic and amphotropic murine leukemia virus (MLV) envelope glycoproteins. Vector particles bearing the modified glycoproteins were produced and analysed. Although conventional FACS studies indicated that viral particles bearing the modified Env could bind to ovarian cancer cells, targeted infection was not achieved. The initial step of virus-cell interaction was further studied using an immunofluorescence technique, which allows visualisation of single retrovirus particles. Vectors bearing chimeric or wild-type glycoproteins bound equally well to cells with or without the targeted receptor, although soluble chimeric glycoproteins bound specifically to FBP. Our results indicate that the incorporation of specific ligands to the virus envelope does not necessarily result in significant enhancement of vector particle binding. A similar interaction was also observed using Env-defective virus particles, suggesting that cellular factors incorporated into the lipid envelope play a dominant role in promoting initial adsorption of virus particles to cells. Significant implications arise from these observations on the interpretation of previous reports on 'targeted' vectors, and for the development of vectors for in vivo gene therapy protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.